Dr. Parker on next steps with mpMRI in prostate cancer
William P. Parker, MD, shares his expectations for the future of multiparametric MRI (mpMRI) in prostate cancer and where micro-ultrasound may fit alongside mpMRI in the paradigm. Parker is a practicing urologist at The University of Kanas Health System and an assistant professor at the University of Kansas Medical Center.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Study evaluates weight management and prostate cancer progression, QOL
June 12th 2024"To me, the most compelling outcome is really the quality-of-life outcomes. General quality of life as well as emotional quality of life improved in the intervention group significantly," says Jill M. Hamilton Reeves, PhD, RD, CSO.
![[68Ga]Ga-PSMA-11 PET/CT shows value in initial staging of prostate cancer](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Furologytimes%2F6583419a0719128d5ec70eb6a2f5729faf857b50-1200x905.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "[68Ga]Ga-PSMA-11 PET/CT shows value in initial staging of prostate cancer")
